A protein in cells may change how brain tumor cells handle DNA damage
Original title: Vimentin loss inhibits DNA damage responses and promotes cancer cell survival.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done with cells in a lab dish.
The short version
In lab tests, brain tumor cells missing a protein called vimentin survived treatment better.
What was studied. Researchers worked with glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary cells in the lab. They squeezed the cells and used genes and drugs to change vimentin levels. Then they hit the cells with treatments that damage DNA.
What they found. Cells with vimentin were better at repairing DNA. This was strongest when the cells were under pressure. Cells without vimentin sensed damage less well and died less often. They survived better after temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary and X-ray radiation. Taking the pressure off the cell nucleus brought DNA repair back.
What this means, and what it doesn't
What it could mean: This may help explain why some tumor cells live through chemo and radiation. It points researchers toward a new idea to study. It does not change any treatment a patient gets today.
What it doesn't mean: This work was done with cells in a lab dish, not in people. It was not a test of a new drug or a new therapy. No one knows yet if it will help patients. It is a long way from everyday care, and it is not a promise of a cure.
Source: PubMed, September 4, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.